Get the Stockscreener App
16.69
1.32%
0.2736
Tyra Biosciences Inc stock is traded at $16.69, with a volume of 120.51K.
It is up +1.32% in the last 24 hours and down -24.51% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
See More
Previous Close:
$16.42
Open:
$16.42
24h Volume:
120.51K
Relative Volume:
0.42
Market Cap:
$879.22M
Revenue:
-
Net Income/Loss:
$-69.13M
P/E Ratio:
-13.91
EPS:
-1.2
Net Cash Flow:
$-50.91M
1W Performance:
-1.61%
1M Performance:
-24.51%
6M Performance:
-6.79%
1Y Performance:
+22.51%
1-Day Range:
$15.95
$16.76
1-Week Range:
$15.28
$17.26
52-Week Range:
$10.60
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Auour Investments LLC Reduces Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Long Term Trading Analysis for (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up Following Insider Buying Activity - MarketBeat
Tyra Biosciences director Nina Kjellson sells $2.28m in stock By Investing.com - Investing.com Australia
Tyra Biosciences director Nina Kjellson sells $2.28m in stock - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Purchases $152,000.00 in Stock - MarketBeat
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock - Investing.com
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock By Investing.com - Investing.com UK
Tyra Biosciences (NASDAQ:TYRA) Trading Down 10.2%Here's What Happened - MarketBeat
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment By Investing.com - Investing.com Australia
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment - Investing.com
Piper Sandler maintains Overweight on Tyra Biosciences stock By Investing.com - Investing.com Canada
Tyra Biosciences stock target lifted, retains buy on clinical trial data - Investing.com Canada
Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug By Investing.com - Investing.com Australia
Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug - Investing.com India
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PR Newswire
Tyra Biosciences (NASDAQ:TYRA) Shares Gap DownWhat's Next? - MarketBeat
Tyra Biosciences' (TYRA) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer - Marketscreener.com
(TYRA) Long Term Investment Analysis - Stock Traders Daily
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PR Newswire
Tyra Biosciences Reports Interim Clinical Proof-Of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer - Marketscreener.com
Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet - MSN
Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week HighWhat's Next? - MarketBeat
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Marketscreener.com
Tyra Biosciences stock soars to 52-week high of $28.86 - Investing.com India
Tyra Biosciences stock soars to 52-week high of $28.86 By Investing.com - Investing.com South Africa
RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc - Yahoo Finance
Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 19,084 Shares of Stock - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Up 4.2%Here's Why - MarketBeat
Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Simply Wall St
Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point - Seeking Alpha
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation - Yahoo Finance
Tyra Biosciences issues warrants in exchange for common stock - Investing.com India
Tyra Biosciences issues warrants in exchange for common stock By Investing.com - Investing.com UK
Tyra raised to buy by BofA ahead of TYRA-300 data readout (NASDAQ:TYRA) - Seeking Alpha
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug - Yahoo Finance
This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - MSN
Tyra Biosciences (NASDAQ:TYRA) Upgraded by Bank of America to Buy - MarketBeat
BofA upgrades Tyra Biosciences shares rating to Buy, raises price target - Investing.com Canada
Tyra Biosciences stock soars to 52-week high of $25.3 By Investing.com - Investing.com Australia
Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 10,035 Shares of Stock - MarketBeat
Tyra Biosciences CEO Harris Todd sells $1.5 million in stock By Investing.com - Investing.com South Africa
Tyra Biosciences CEO Harris Todd sells $1.5 million in stock - Investing.com
Tyra Biosciences To Present Initial SURF301 Study Results At The ENA Symposium Next Week - RTTNews
Tyra Biosciences (NASDAQ:TYRA) Hits New 1-Year HighHere's What Happened - MarketBeat
Tyra Biosciences stock soars to 52-week high of $25.3 - Investing.com
Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc - Yahoo Finance
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tyra Biosciences Inc Stock (TYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kjellson Nina S | Director |
Nov 01 '24 |
Sale |
16.56 |
27,493 |
455,272 |
458,506 |
| Kjellson Nina S | Director |
Oct 30 '24 |
Sale |
16.17 |
11,078 |
179,120 |
472,207 |
| Fuhrman Alan | Chief Financial Officer |
Oct 30 '24 |
Buy |
16.00 |
9,500 |
151,954 |
12,849 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):